Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment

Amandeep Mann, Sharon Miksys, Anna Lee, Deborah C. Mash, Rachel F. Tyndale

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Cytochrome P450 (CYP) 2D6, an enzyme found in the liver and the brain, is involved in the metabolism of numerous centrally acting drugs (e.g. antidepressants, neuroleptics, opiates), endogenous neurochemicals (e.g. catecholamines) and in the inactivation of neurotoxins (e.g. pesticides, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)). Although CYP2D6 is essentially an uninducible enzyme in the liver, we show that smokers have higher CYP2D6 in the brain, especially in the basal ganglia. In order to determine whether nicotine, a component of cigarette smoke, could increase brain CYP2D, African Green monkeys were treated chronically with nicotine (0.05 mg/kg for 2 days, then 0.15 mg/kg for 2 days followed by 0.3 mg/kg for 18 days s.c., b.i.d.). Monkeys treated with nicotine showed significant induction of CYP2D in brain when compared to saline-treated animals as detected by western blotting and immunocytochemistry. No changes in liver CYP2D were observed in nicotine-treated monkeys. Induction was observed in various brain regions including those affected in Parkinson's disease (PD) such as substantia nigra (3-fold, p = 0.01), putamen (2.1-fold, p = 0.001) and brainstem (2.4-fold, p = 0.001), with the caudate nucleus approaching significance (1.6-fold, p = 0.07). Immunocytochemistry revealed that the expression of CYP2D in both saline- and nicotine-treated monkeys is cell-specific particularly in the cerebellum, frontal cortex and hippocampus. These results suggest that monkey brain expresses CYP2D, which is induced in specific cells and brain regions upon chronic nicotine treatment. Smokers, or those using nicotine treatment, may have higher levels of brain CYP2D6 that may result in altered localized CNS drug metabolism and inactivation of neurotoxins.

Original languageEnglish (US)
Pages (from-to)1147-1155
Number of pages9
JournalNeuropharmacology
Volume55
Issue number7
DOIs
StatePublished - Dec 1 2008

Fingerprint

Nicotine
Haplorhini
Cytochrome P-450 CYP2D6
Brain
Enzymes
Pharmaceutical Preparations
Neurotoxins
Therapeutics
Liver
Immunohistochemistry
Cercopithecus aethiops
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Opioid Peptides
Caudate Nucleus
Putamen
Frontal Lobe
Substantia Nigra
Basal Ganglia
Pesticides
Smoke

Keywords

  • Brain drug metabolism
  • CYP2D6
  • Nicotine
  • Non-human primate
  • Parkinson's disease
  • Smoking

Cite this

Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. / Mann, Amandeep; Miksys, Sharon; Lee, Anna; Mash, Deborah C.; Tyndale, Rachel F.

In: Neuropharmacology, Vol. 55, No. 7, 01.12.2008, p. 1147-1155.

Research output: Contribution to journalArticle

Mann, Amandeep ; Miksys, Sharon ; Lee, Anna ; Mash, Deborah C. ; Tyndale, Rachel F. / Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. In: Neuropharmacology. 2008 ; Vol. 55, No. 7. pp. 1147-1155.
@article{1511e10f9e87480690bc5639ef7fb3df,
title = "Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment",
abstract = "Cytochrome P450 (CYP) 2D6, an enzyme found in the liver and the brain, is involved in the metabolism of numerous centrally acting drugs (e.g. antidepressants, neuroleptics, opiates), endogenous neurochemicals (e.g. catecholamines) and in the inactivation of neurotoxins (e.g. pesticides, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)). Although CYP2D6 is essentially an uninducible enzyme in the liver, we show that smokers have higher CYP2D6 in the brain, especially in the basal ganglia. In order to determine whether nicotine, a component of cigarette smoke, could increase brain CYP2D, African Green monkeys were treated chronically with nicotine (0.05 mg/kg for 2 days, then 0.15 mg/kg for 2 days followed by 0.3 mg/kg for 18 days s.c., b.i.d.). Monkeys treated with nicotine showed significant induction of CYP2D in brain when compared to saline-treated animals as detected by western blotting and immunocytochemistry. No changes in liver CYP2D were observed in nicotine-treated monkeys. Induction was observed in various brain regions including those affected in Parkinson's disease (PD) such as substantia nigra (3-fold, p = 0.01), putamen (2.1-fold, p = 0.001) and brainstem (2.4-fold, p = 0.001), with the caudate nucleus approaching significance (1.6-fold, p = 0.07). Immunocytochemistry revealed that the expression of CYP2D in both saline- and nicotine-treated monkeys is cell-specific particularly in the cerebellum, frontal cortex and hippocampus. These results suggest that monkey brain expresses CYP2D, which is induced in specific cells and brain regions upon chronic nicotine treatment. Smokers, or those using nicotine treatment, may have higher levels of brain CYP2D6 that may result in altered localized CNS drug metabolism and inactivation of neurotoxins.",
keywords = "Brain drug metabolism, CYP2D6, Nicotine, Non-human primate, Parkinson's disease, Smoking",
author = "Amandeep Mann and Sharon Miksys and Anna Lee and Mash, {Deborah C.} and Tyndale, {Rachel F.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1016/j.neuropharm.2008.07.017",
language = "English (US)",
volume = "55",
pages = "1147--1155",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment

AU - Mann, Amandeep

AU - Miksys, Sharon

AU - Lee, Anna

AU - Mash, Deborah C.

AU - Tyndale, Rachel F.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Cytochrome P450 (CYP) 2D6, an enzyme found in the liver and the brain, is involved in the metabolism of numerous centrally acting drugs (e.g. antidepressants, neuroleptics, opiates), endogenous neurochemicals (e.g. catecholamines) and in the inactivation of neurotoxins (e.g. pesticides, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)). Although CYP2D6 is essentially an uninducible enzyme in the liver, we show that smokers have higher CYP2D6 in the brain, especially in the basal ganglia. In order to determine whether nicotine, a component of cigarette smoke, could increase brain CYP2D, African Green monkeys were treated chronically with nicotine (0.05 mg/kg for 2 days, then 0.15 mg/kg for 2 days followed by 0.3 mg/kg for 18 days s.c., b.i.d.). Monkeys treated with nicotine showed significant induction of CYP2D in brain when compared to saline-treated animals as detected by western blotting and immunocytochemistry. No changes in liver CYP2D were observed in nicotine-treated monkeys. Induction was observed in various brain regions including those affected in Parkinson's disease (PD) such as substantia nigra (3-fold, p = 0.01), putamen (2.1-fold, p = 0.001) and brainstem (2.4-fold, p = 0.001), with the caudate nucleus approaching significance (1.6-fold, p = 0.07). Immunocytochemistry revealed that the expression of CYP2D in both saline- and nicotine-treated monkeys is cell-specific particularly in the cerebellum, frontal cortex and hippocampus. These results suggest that monkey brain expresses CYP2D, which is induced in specific cells and brain regions upon chronic nicotine treatment. Smokers, or those using nicotine treatment, may have higher levels of brain CYP2D6 that may result in altered localized CNS drug metabolism and inactivation of neurotoxins.

AB - Cytochrome P450 (CYP) 2D6, an enzyme found in the liver and the brain, is involved in the metabolism of numerous centrally acting drugs (e.g. antidepressants, neuroleptics, opiates), endogenous neurochemicals (e.g. catecholamines) and in the inactivation of neurotoxins (e.g. pesticides, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)). Although CYP2D6 is essentially an uninducible enzyme in the liver, we show that smokers have higher CYP2D6 in the brain, especially in the basal ganglia. In order to determine whether nicotine, a component of cigarette smoke, could increase brain CYP2D, African Green monkeys were treated chronically with nicotine (0.05 mg/kg for 2 days, then 0.15 mg/kg for 2 days followed by 0.3 mg/kg for 18 days s.c., b.i.d.). Monkeys treated with nicotine showed significant induction of CYP2D in brain when compared to saline-treated animals as detected by western blotting and immunocytochemistry. No changes in liver CYP2D were observed in nicotine-treated monkeys. Induction was observed in various brain regions including those affected in Parkinson's disease (PD) such as substantia nigra (3-fold, p = 0.01), putamen (2.1-fold, p = 0.001) and brainstem (2.4-fold, p = 0.001), with the caudate nucleus approaching significance (1.6-fold, p = 0.07). Immunocytochemistry revealed that the expression of CYP2D in both saline- and nicotine-treated monkeys is cell-specific particularly in the cerebellum, frontal cortex and hippocampus. These results suggest that monkey brain expresses CYP2D, which is induced in specific cells and brain regions upon chronic nicotine treatment. Smokers, or those using nicotine treatment, may have higher levels of brain CYP2D6 that may result in altered localized CNS drug metabolism and inactivation of neurotoxins.

KW - Brain drug metabolism

KW - CYP2D6

KW - Nicotine

KW - Non-human primate

KW - Parkinson's disease

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=54049130764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049130764&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2008.07.017

DO - 10.1016/j.neuropharm.2008.07.017

M3 - Article

C2 - 18687346

AN - SCOPUS:54049130764

VL - 55

SP - 1147

EP - 1155

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 7

ER -